R. Paridaens

791 total citations
11 papers, 360 citations indexed

About

R. Paridaens is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, R. Paridaens has authored 11 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in R. Paridaens's work include Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). R. Paridaens is often cited by papers focused on Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). R. Paridaens collaborates with scholars based in Belgium, Switzerland and United Kingdom. R. Paridaens's co-authors include Beat Thürlimann, D. Serin, Silvana Lanzalone, Wouter Hendrickx, Jacques Bonneterre, Robin Murray, E. Di Salle, G. Piscitelli, Hoffmann-La Roche and Julie Decock and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.

In The Last Decade

R. Paridaens

10 papers receiving 346 citations

Peers

Countries citing papers authored by R. Paridaens

Since Specialization

Citations

This map shows the geographic impact of R. Paridaens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Paridaens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Paridaens more than expected).

Fields of papers citing papers by R. Paridaens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Paridaens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Paridaens. The network helps show where R. Paridaens may publish in the future.

Co-authorship network of co-authors of R. Paridaens

This figure shows the co-authorship network connecting the top 25 collaborators of R. Paridaens. A scholar is included among the top collaborators of R. Paridaens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Paridaens. R. Paridaens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel 2014 ·Breast Cancer Research and Treatment ·Christof Vulsteke, Alena M. Pfeil, Matthias Schwenkglenks, Ruth Pettengell, Thomas D. Szucs, Diether Lambrechts, Marc Peeters, Peter A. van Dam, (unknown), (unknown), P. Neven, R. Paridaens, Hans Wildiers	24
2	198 Specific Adverse Events Predict Survival Benefit in Early Breast Cancer Patients Treated with Exemestane in the Dutch/Belgian TEAM Trial 2012 ·European Journal of Cancer ·D.B.Y. Fontein, Daniel Houtsma, E.T.M. Hille, (unknown), Hein Putter, (unknown), Luc Dirix, R. Paridaens, C.J.H. Van de Velde, (unknown)	0
3	Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence 2008 ·Breast Cancer Research and Treatment ·(unknown), Luc Dirix, Patrick Neven, A. Prové, Paul M. Clément, Pierre Squifflet, Frédéric Amant, Tomáš Skácel, R. Paridaens	22
4	Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera ofpatients with early-stage and inflammatory breast cancer 2008 ·The International Journal of Biological Markers ·Julie Decock, Nataša Obermajer, (unknown), Wouter Hendrickx, R. Paridaens, Janko Kos	58
5	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial 2007 ·Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, (unknown), Aron Goldhirsch	106
6	Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas 2007 ·Disease Markers ·Julie Decock, Wouter Hendrickx, M. Drijkoningen, Hans Wildiers, Patrick Neven, Ann Smeets, R. Paridaens	19
7	Vorozole (Rivizor???): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure 1998 ·Anti-Cancer Drugs ·R. Paridaens, (unknown), M. Nooij, Jan G.M. Klijn, Stephen Houston, L.V.A.M. Beex, (unknown), Eva Tomiak, A. Van Vreckem, Christine Langenaeken, M. van Glabbeke, Martine Piccart	4
8	Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study 1997 ·European Journal of Cancer ·Beat Thürlimann, R. Paridaens, D. Serin, Jacques Bonneterre, Hoffmann-La Roche, Robin Murray, E. Di Salle, Silvana Lanzalone, (unknown), G. Piscitelli	119
9	Interim Results on a Randomized Trial of Mitomycin C in Combination with Orchidectomy for Newly Diagnosed Metastatic Prostate Cancer 1995 ·American Journal of Clinical Oncology ·Frank Vandenbroucke, (unknown), (unknown), (unknown), J Casselman, Ignace Billiet, L. Vanuytsel, R. Paridaens, (unknown)	3
10	An overview of the EORTC breast cancer cooperative group's activities 1983 ·European Journal of Cancer and Clinical Oncology ·R. Paridaens, W Mattheiem, J.A. van Dongen, H.T. Mouridsen, Nicole Rotmensz, Richard Sylvester	4
11	579 Chemotherapy with estrogenic recruitment in advanced breast cancer. preliminary results of a phase II study of the E.O.R.T.C. breast cancer cooperative group 1983 ·Journal of Steroid Biochemistry ·R. Paridaens, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact